December 20, 2016 / 9:52 PM / 8 months ago

BRIEF-Galapagos NV says SAPHIRA 1 topline shows competitive clinical results in G551D patients

Dec 20 (Reuters) - Galapagos Nv :

* Galapagos NV says GLPG1837 was generally well tolerated when dosed up to 500 mg twice daily for 14 days

* Galapagos NV says SAPHIRA 1 topline shows competitive clinical results in G551D patients

* A statistically significant dose dependent decrease in sweat chloride concentration was observed Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below